|
|
| (28 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| {{Bivalirudin}}
| | |valign=top| |
| {{CMG}}; {{AE}} {{JH}}
| | |+ |
| | | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| '''''For patient information about Bivalirudin, click [[Bivalirudin (patient information)|here]].'''''
| | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| {{SB}} ANGIOMAX<sup>®</sup>
| | |- |
| | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| ==Overview==
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| '''Bivalirudin''' (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible [[direct thrombin inhibitor]] (DTI).
| | |} |
| | |
| Chemically, it is a synthetic congener of the naturally occurring drug [[hirudin]] (found in the saliva of the medicinal leech ''Hirudo medicinalis'').
| |
| | |
| Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as [[heparin]]. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of [[thrombin]]. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for [[Heparin-induced thrombocytopenia|Heparin Induced Thrombocytopenia]]/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
| |
| | |
| Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable [[angina]], unstable angina (UA), non-ST segment elevation myocardial infarction ([[NSTEMI]]), and ST-segment elevation myocardial infarction ([[STEMI]]) undergoing [[PCI]] in 7 major randomized trials.
| |
| ==Category==
| |
| | |
| Direct thrombin inhibitor.
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ====Label Title==== | |
| | |
| ''' [[Bivalirudin indications and usage|Indications and Usage]]'''
| |
| '''| [[Bivalirudin dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Bivalirudin dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Bivalirudin contraindications|Contraindications]]'''
| |
| '''| [[Bivalirudin warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Bivalirudin adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Bivalirudin drug interactions|Drug Interactions]]'''
| |
| '''| [[Bivalirudin use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Bivalirudin overdosage|Overdosage]]'''
| |
| '''| [[Bivalirudin description|Description]]'''
| |
| '''| [[Bivalirudin clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Bivalirudin nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Bivalirudin clinical studies|Clinical Studies]]'''
| |
| '''| [[Bivalirudin how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Bivalirudin patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Bivalirudin labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action== | |
| | |
| Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process. It cleaves [[fibrinogen]] into fibrin monomers, activates Factor V, VIII, and XIII, allowing fibrin to develop a covalently cross-linked framework that stabilizes the thrombus. [[Thrombin]] also promotes further [[thrombin]] generation, and activates platelets, stimulating aggregation and granule release. The binding of bivalirudin to thrombin is reversible as [[thrombin]] slowly cleaves the bivalirudin-Arg<sub>3</sub>-Pro<sub>4</sub> bond, resulting in recovery of thrombin active site functions.
| |
| | |
| '''Pharmacokinetics'''
| |
| | |
| *Following an IV bolus of bivalirudin of 1 mg/kg and a 4-hour 2.5 mg/kg/h IV infusion a mean steady state concentration of 12.3 ± 1.7 µg/mL is achieved
| |
| | |
| *Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage
| |
| | |
| *Half-life:
| |
| | |
| : Normal renal function (≥ 90 mL/min) = 25 minutes | |
| | |
| : Mild renal dysfunction (60–89 mL/min) = 22 minutes
| |
| | |
| : Moderate renal dysfunction (30-59 mL/min) = 34 minutes | |
| | |
| : Severe renal dysfunction (≤ 29 mL/min) = 57 minutes | |
| | |
| : Dialysis-dependent = 3.5 hours
| |
| | |
| *Clearance is reduced approximately 20% in patients with moderate and severe renal impairment and by 80% in [[dialysis]]-dependent patients
| |
| | |
| *Bivalirudin is hemodialyzable and approximately 25% is cleared by hemodialysis.
| |
| | |
| '''Pharmacodynamics'''
| |
| | |
| [[Coagulation]] times return to baseline approximately 1 hour following cessation of bivalirudin administration.
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |